COVID-19 Therapeutics Use by Social Deprivation Index in England, July 2020–April 2023

COVID Pub Date : 2024-05-15 DOI:10.20944/preprints202403.1157.v1

Angela Falola, Hanna Squire, Sabine Bou-Antoun, Alessandra Løchen, Colin S. Brown, Alicia Demirjian

{"title":"COVID-19 Therapeutics Use by Social Deprivation Index in England, July 2020–April 2023","authors":"Angela Falola, Hanna Squire, Sabine Bou-Antoun, Alessandra Løchen, Colin S. Brown, Alicia Demirjian","doi":"10.20944/preprints202403.1157.v1","DOIUrl":null,"url":null,"abstract":"Coronavirus disease-19 (COVID-19) has disproportionately affected certain demographics in England, exacerbating existing health disparities. Effective therapeutics are a critical line of defence against COVID-19, particularly for patients at elevated risk for severe disease. Surveillance systems were established to monitor the usage of COVID-19 therapeutics in hospital and community settings and to inform stewardship. Three antiviral therapies—nirmatrelvir plus ritonavir (Paxlovid®), remdesivir (Veklury®), and molnupiravir (Lagevrio®)—and two neutralising monoclonal antibody therapies (nMAbs)—sotrovimab (Xevudy®) and casirivimab with imdevimab (Ronapreve®)—were in use in England between July 2020 and April 2023. This paper aims to illuminate trends in the utilisation of COVID-19 therapeutics treatment in both hospital and community settings, stratified by the Index of Multiple Deprivation (IMD) in England. Chapter 3 of the English Surveillance Programme for Antimicrobial Utilisation and Resistance (ESPAUR) Report 2022 to 2023 also discusses the epidemiological surveillance of these five directly acting antiviral COVID-19 therapeutics’ use in England between 2022 and 2023.","PeriodicalId":72714,"journal":{"name":"COVID","volume":"63 11","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-05-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"COVID","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.20944/preprints202403.1157.v1","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

Coronavirus disease-19 (COVID-19) has disproportionately affected certain demographics in England, exacerbating existing health disparities. Effective therapeutics are a critical line of defence against COVID-19, particularly for patients at elevated risk for severe disease. Surveillance systems were established to monitor the usage of COVID-19 therapeutics in hospital and community settings and to inform stewardship. Three antiviral therapies—nirmatrelvir plus ritonavir (Paxlovid®), remdesivir (Veklury®), and molnupiravir (Lagevrio®)—and two neutralising monoclonal antibody therapies (nMAbs)—sotrovimab (Xevudy®) and casirivimab with imdevimab (Ronapreve®)—were in use in England between July 2020 and April 2023. This paper aims to illuminate trends in the utilisation of COVID-19 therapeutics treatment in both hospital and community settings, stratified by the Index of Multiple Deprivation (IMD) in England. Chapter 3 of the English Surveillance Programme for Antimicrobial Utilisation and Resistance (ESPAUR) Report 2022 to 2023 also discusses the epidemiological surveillance of these five directly acting antiviral COVID-19 therapeutics’ use in England between 2022 and 2023.

查看原文本刊更多论文

COVID-19 2020 年 7 月至 2023 年 4 月英格兰按社会贫困指数分列的治疗药物使用情况

冠状病毒病-19（COVID-19）对英格兰某些人口群体的影响格外严重，加剧了现有的健康差距。有效的治疗方法是抵御 COVID-19 的一道关键防线，尤其是对严重疾病风险较高的患者而言。我们建立了监控系统，以监测 COVID-19 治疗药物在医院和社区环境中的使用情况，并为监管工作提供信息。2020 年 7 月至 2023 年 4 月期间，英格兰使用了三种抗病毒疗法--尼尔马特韦加利托那韦（Paxlovid®）、雷米地韦（Veklury®）和莫鲁吡韦（Lagevrio®），以及两种中和单克隆抗体疗法（nMAbs）--索罗维单抗（Xevudy®）和卡西利韦单抗加伊莫德单抗（Ronapreve®）。本文旨在阐明医院和社区环境中 COVID-19 疗法的使用趋势，并根据英格兰的多重贫困指数 (IMD) 进行分层。英格兰抗菌药物使用和耐药性监测计划（ESPAUR）2022 年至 2023 年报告》第 3 章还讨论了 2022 年至 2023 年期间英格兰对这五种直接作用抗病毒 COVID-19 疗法使用情况的流行病学监测。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

COVID

自引率

0.00%

发文量